The last annual meeting was in Lund, Sweden in May 2015. At this meeting a new related training network was launched called MELGEN (see the MELGEN section of the web site). MELGEN is a Marie Curie training network funded by the EU Horizon 2020 in which 17 new PhD students will be trained across Europe.
Over 60 researchers attended the joint GenoMEL/BioGenoMEL meeting in Valencia in May 2014. There were over 40 scientific presentations of world leading research with additional participation over the Internet. Such e-participation was trialled at this event and is likely to feature again in future meetings. Our thanks go to Dr. Eduardo Nagore and the Fundacion Instituto Valenciano de Oncologia for hosting the meeting.
Researchers at the 2014 meeting
As part of their annual Christmas message to clients, IRT sends a newsletter highlighting a worthy cause. This Christmas IRT highlighted skin cancer and their UK office choose to support GenoMEL. IRT is the leading international horse transport company with its global headquarters in Australia and so skin awareness is a particularly relevant issue. We are very grateful for their donation of £1,500.
Rachel Barber recently completed the Great North Run and asked for sponsorship in memory of her dear friend Jenny, who she lost to melanoma. Rachel has raised over £500 to support GenoMEL’s research. Donations are still being accepted at JustGiving.com Congratulations to Rachel and thank you to all her sponsors.
Rachel Barber with her Great North Run medal
Geoff Walker recently completed Ironman France and asked for sponsorship in memory of a dear friend, Bernie Jackson, who died from melanoma earlier this year. The challenge involved over 140 miles of swimming, biking and running and Geoff has raised over £2,000 to support GenoMEL’s research. Donations are still being accepted at JustGiving.com Congratulations to Geoff and thank you to all his sponsors.
A GenoMEL study of somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status has been published in the Journal of Investigative Dermatology. This study set out to investigate whether inheriting a CDKN2Amutation influences the mutations found within the actual tumour. Led by researchers in Sweden, it involved colleagues from more than eight different research groups and samples from over 100 patients.